Suppressive effect of dipyridamole on the proteinuria of aminonucleoside nephrosis in rat.
The suppressive effect of dipyridamole on the proteinuria of aminonucleoside nephrosis and protamine-induced proteinuria, was investigated. Male Wistar rats were given puromycin aminonucleoside (80 mg/kg s.c.) or protamine sulfate (20 mg/kg i.v.), and the urine was collected in metabolic cages. The content of proteins in the urine was determined by using a continuous gradient microgel electrophoresis procedure. Dipyridamole (20 mg/kg p.o.) suppressed the excretion of albumin and proteins larger than albumin (HMP) in aminonucleoside nephrosis. But the excertion of proteins smaller than albumin (LMP) was not affected by dipyridamole. Dipyridamole also suppressed the excertion of HMP in protamine-induced proteinuria, though the excretion of albumin and LMP was not affected. Puromycin aminonucleoside and protamine sulfate were known to cause renal glomerular epithelial changes referred to as "fusion" of foot processes. Since dipyridamole was effective in suppressing the both types of proteinuria, this drug was considered to improve the damaged renal glomerular barrier for plasma proteins.
D000419:Albuminuria / Q000188:drug therapy; D000818:Animals; D004176:Dipyridamole / Q000627:therapeutic use*; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000652:urine*; D011479:Protamines / Q000494:pharmacology; D011507:Proteinuria / Q000188:drug therapy*; D011691:Puromycin / Q000031:analogs & derivatives*; D011692:Puromycin Aminonucleoside / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors
D011479:Protamines; D011691:Puromycin; D011692:Puromycin Aminonucleoside; D004176:Dipyridamole